Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

Abstract: A 64‐year‐old woman, who had presented with a 30‐year history of refractory asthma, and been treated with anti‐allergic drug therapy, inhaled corticosteroids, a long‐acting beta‐agonist, and a long‐acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.

ePDFPDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @worldallergy: WAO TV: Newer technologies to treat allergies and asthma - January 2019. Pinkus Goldberg, MD, Allergy Partners & Indiana…
2hreplyretweetfavorite
Interasma RT @Aller_MD: Enterovirus as trigger of coeliac disease: Enterovirus in early childhood could be a trigger for later coeliac disease in chi…
2hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Anaphylaxis Treatment: How to Avert This Severe Allergic Reaction | Everyday Health https://t.co/8AM98iAzzn, see m…
2hreplyretweetfavorite
Interasma RT @Aller_MD: “IMAGES IN CLINICAL MEDICINE: Sporotrichosis” https://t.co/Tbcl83VSUT https://t.co/v882YVbh8v
2hreplyretweetfavorite
Interasma Interasma - Association of plasma soluble CD14 level with #asthma severity in adults: a case control study in China https://t.co/OCQ2S7Z22e
2hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma